Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimum detectable dose as a measure of bioassay programme capability.

E H Carbaugh1

  • 1Pacific Northwest National Laboratory, PO Box 999, Richland, WA 99352, USA. gene.carbaugh@pnl.gov

Radiation Protection Dosimetry
|October 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Contingency Plan for Catastrophic Loss of Bioassay Services.

Health physics·2018
Same author

Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.

Radiation protection dosimetry·2008
Same author

Two case studies of highly insoluble plutonium inhalation with implications for bioassay.

Radiation protection dosimetry·2003
See all related articles

This study proposes using the minimum detectable dose (MDD) to assess bioassay program effectiveness for rare intakes. MDD provides a direct measure of capability, ensuring compliance with dose limits.

Area of Science:

  • Radiological protection
  • Bioassay analysis
  • Radiation detection

Background:

  • Assessing the effectiveness of bioassay programs is crucial for radiation safety.
  • Current methods may not adequately reflect program capability for rare intake scenarios.
  • Standardized metrics are needed to demonstrate compliance with performance criteria.

Purpose of the Study:

  • To introduce and define the Minimum Detectable Dose (MDD) as a metric for bioassay program capability.
  • To establish a method for expressing bioassay program capability in units directly related to dose limits.
  • To provide a framework for optimizing bioassay monitoring strategies.

Main Methods:

  • Adapting the analytical statistic Minimum Detectable Amount (MDA) for dose assessment.

Related Experiment Videos

  • Calculating the dose resulting from MDA detection at a specific time post-intake.
  • Utilizing MDD for tabulation and plotting to evaluate monitoring program effectiveness.

    • Main Results:

    • MDD offers a direct measure of bioassay program capability in dose units.
    • The MDD concept facilitates clear demonstration of compliance with performance standards.
    • MDD can be used to compare and optimize different bioassay monitoring strategies.

    Conclusions:

    • The Minimum Detectable Dose (MDD) is a valuable metric for evaluating bioassay programs, especially for rare intakes.
    • MDD enhances the ability to demonstrate compliance with radiation dose limits.
    • Integrating cost-benefit analysis with MDD can lead to optimized bioassay program design.